NOI -Illumina Infinium Methylation Screening Array | SAM.gov Opportunity | G2X

NOI -Illumina Infinium Methylation Screening Array

Solicitation75N98026Q00600Notice typeCombined Synopsis/Solicitation

Attachments

1 file

Name	Type	Posted	Actions
Sol_75N98026Q00600.pdf	PDF	Jun 11, 2026	Download

Version History

NOI -Illumina Infinium Methylation Screening Array

Combined Synopsis75N98026Q00600Jun 11, 2026 · v1

LatestViewing

Opportunity Summary

The National Institutes of Health (NIH), Office of Logistics and Acquisition Operations, is issuing this combined synopsis/solicitation as a notice of intent to award a non-competitive, firm-fixed-price purchase order to Illumina, Inc. The procurement is for 20 Infinium Methylation Screening Array-48 Kits in support of the National Heart, Lung, and Blood Institute (NHLBI) Division of Intramural Research, specifically the Laboratory of Genomic Instability and Cardiopulmonary Outcomes. These proprietary kits are required to perform assays at the National Institute on Aging Laboratory of Neurogenetics using existing Illumina iScan and Infinium Automated Pipetting systems.

This acquisition is classified under NAICS 325413 In-Vitro Diagnostic Substance Manufacturing and PSC 6550 IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS. The requirement is not set aside for small business. Illumina, Inc. is the sole manufacturer and source for these products, which are protected by patents and trade secrets, and no other manufacturer produces a functionally equivalent product compatible with the government's installed equipment.

The solicitation, identified as 75N98026Q00600, was published on June 11, 2026, and includes one PDF attachment. Responses are due by June 18, 2026. Nicholas S. Capobianco is the designated point of contact for this requirement, which is being conducted under the authority of FAR 12.603 and FAR 6.302-3.

Generated by Lumen AI

Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.

Opportunity Summary

Opportunity Details

Response deadline: Jun 18, 20262 days remaining
NAICS: 325413 (opens in new tab)
PSC: 6550 (opens in new tab)
Set aside: —
Published: Jun 11, 2026
Updated: Jun 11, 2026
Agency: NATIONAL INSTITUTES OF HEALTH (opens in new tab)
Office: NATIONAL INSTITUTES OF HEALTH OLAO
Department: —
Source: View on SAM.gov (opens in new tab)

Contact and place of performance

Point of contact: CAPOBIANCO, NICHOLAS S

Place of performance: Not specified

Original Description

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued.
(ii) The solicitation number is 75N98026Q00600. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (brand-name).
This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii).
The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122 for twenty (20) Infinium Methylation Screening Array-48 Kits (Catalog No. 20112611) in support of the NHLBI Division of Intramural Research, Laboratory of Genomic Instability and Cardiopulmonary Outcomes (LoGICO). Illumina is the sole manufacturer and source of the Infinium Methylation Screening Array, a proprietary BeadChip product protected by patents and trade secrets, and the only methylation array compatible with the Illumina iScan System and Infinium Automated Pipetting System with ILASS already installed at the NIA Laboratory of Neurogenetics where the assays will be performed. No other manufacturer produces a functionally equivalent product, and Illumina has certified in writing that it has not authorized any third-party intermediary to provide the Illumina products required for this transaction (Quotation No. 4791799).(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026.(iv) The associated NAICS code is 325413 ¿ In-Vitro Diagnostic Substance Manufacturing, and the small business size standard is 1,250 employees. This requirement is not set aside for small business.